Weekly Digest – May 2026 Weekly Digest – May 2026 07 May 2026: InnoCare Pharma’s independently developed CDH17-targeted ADC innovative drug ICP B208 has been approved for clinical trials InnoCare Pharma has expanded its ADC pipeline after receiving National Medical […]
Weekly Digest – May 2026 Weekly Digest – May 2026 07 May 2026: ArriVent announces IND clearance for novel tetravalent MUC16/NaPi2b targeting ADC ARR-002 with initial focus in Ovarian and Endometrial cancers ArriVent BioPharma has received IND clearance for ARR-002, […]
Weekly Digest – May 2026 Weekly Digest – May 2026 29 April 2026: The NMPA has granted BTD for B7-H3-targeted ADC HS-20093 for castration-resistant prostate cancer Hansoh Pharmaceutical announced that China’s National Medical Products Administration has granted Breakthrough Therapy designation […]
Weekly Digest – May 2026 Weekly Digest – May 2026 30 April 2026: Alphamab Oncology announces IND application for TROP2/HER3 bispecific ADC JSKN016SC officially accepted by CDE Alphamab Oncology announced that the IND application for its TROP2/HER3 bispecific antibody–drug conjugate […]
Weekly Digest – May 2026 Weekly Digest – May 2026 28 April 2026: Taiho Pharmaceutical and Araris Biotech AG advance ADC ARC-02 into phase 1 clinical development Taiho Oncology, Taiho Pharmaceutical, and Araris Biotech announced that the U.S. FDA has […]
Weekly Digest – May 2026 Weekly Digest – May 2026 29 April 2026: SYS6051 obtains clinical trial approval in the U.S. CSPC Pharmaceutical Group announced that the U.S. FDA has approved the Investigational New Drug application for its antibody drug […]
Weekly Digest – May 2026 Weekly Digest – May 2026 24 April 2026: Novartis withdraws EMA application for adding new indication for Pluvicto Novartis announced that it has withdrawn its Type II variation application with the European Medicines Agency for […]
Weekly Digest – April 2026 Weekly Digest – April 2026 20 April 2026: U.S. FDA grants Priority Review to sBLA for PADCEV + Keytruda as perioperative treatment for MIBC regardless of Cisplatin eligibility U.S. Food and Drug Administration has granted […]
Weekly Digest – April 2026 Weekly Digest – April 2026 22 April 2026: Trastuzumab Ruikang has received BTD from China’s NMPA for the treatment of HER2‑positive breast cancer Jiangsu Hengrui Pharmaceuticals announced that its HER2-targeting ADC Trastuzumab Ruikang in combination […]
Weekly Digest – April 2026 Weekly Digest – April 2026 22 April 2026: SHR‑A2102 has received BTD from China’s NMPA for the treatment of cervical cancer Jiangsu Hengrui Pharmaceuticals announced that its SHR-A2102 ADC has been granted Breakthrough Therapy Designation […]
